FORE Biotherapeutics
Precision oncology company developing cancer therapies guided by proprietary functional genomics.
About
FORE Biotherapeutics is a precision oncology company dedicated to pioneering the development of novel cancer therapies. Their approach is deeply rooted in science and innovation, utilizing proprietary functional genomics to guide their therapeutic development. Their vision is to compassionately contribute to solving cancer. Teams look it up for Healthcare, Drug Development, Genomics.
Frequently asked
What does FORE Biotherapeutics do?
FORE Biotherapeutics is a Healthcare company that offers Software. Teams look it up for Drug Development, Genomics, Next Generation Sequencing. It is based in Philadelphia, United States and was founded in 2011. It was formerly known as NovellusDX. Public records show about 56 people and $232M raised. Compare it on funding, headcount, reviews and nearby alternatives rather than the marketing line alone.
How much funding has FORE Biotherapeutics raised?
FORE Biotherapeutics has raised a total of $232M in funding. The most recent round on record is Series D-2 Extension.
Where is FORE Biotherapeutics headquartered?
FORE Biotherapeutics is headquartered in Philadelphia, United States.
When was FORE Biotherapeutics founded?
FORE Biotherapeutics was founded in 2011.
What industry does FORE Biotherapeutics operate in?
FORE Biotherapeutics operates in Healthcare, Drug Development, Genomics, Next Generation Sequencing, Biotech.
How many employees does FORE Biotherapeutics have?
FORE Biotherapeutics has approximately 56 people on record.
Strength of the site’s backlink profile, on Ahrefs’ 0-100 Domain Rating scale. Licensed third-party data, not our opinion.
How well an AI agent can read and use this site: structured data, clean markup, and whether key facts are reachable without running JavaScript. We scan the live site.
Google PageSpeed mobile performance for the company’s own site. Measured by Google, not by us.